Contents

Contributors xiii

1. Physiology of erythropoiesis 1
   U. Testa

2. Biology of EPO and EPO-receptor 67
   C. Lacombe and P. Mayeux

3. The role of erythropoietin receptor expression on tumor cells 81
   J. Fandrey

4. Problems associated with erythropoietin receptor
determination on tumor cells 103
   A. Österborg

5. Definition, classification and characterization of anemia
   in cancer 117
   M. R. Nowrousian

6. Pathophysiology of anemia in cancer 149
   M. R. Nowrousian

7. Prevalence and incidence of anemia and risk factors for
   anemia in patients with cancer 189
   H. Ludwig

8. Significance of anemia in cancer chemotherapy 207
   M. R. Nowrousian

9. Incidence and impact of anemia in radiation oncology 249
   J. Dunst and M. Molls

10. Relationship between hemoglobin levels and tumor
    oxygenation 265
    P. Vaupel, A. Mayer and M. Höckel
x  Contents

11. Tumor hypoxia and therapeutic resistance 283
   P. Vaupel and M. Höckel

12. Symptoms of anemia 307
   R. Pirker

13. Impact of anemia and red blood cell transfusion on
   organ function 317
   M. R. Nowrousian

14. Relationship of hemoglobin, fatigue, and quality of life in
   anemic cancer patients 369
   Z. Butt and D. Cella

15. When to use red blood cell transfusions in cancer patients
   with solid tumours? 393
   J. K. Jacob and P. J. Barrett-Lee

16. Pharmacology, pharmacokinetics and safety of recombinant
   human erythropoietin preparations 407
   W. Jelkmann

17. Epoetin treatment of anemia associated with multiple myeloma
   and non-Hodgkin’s lymphoma 433
   A. Österborg

18. rhEPO in anemic patients with solid tumors and
   chemotherapy – efficacy and safety 449
   M. R. Nowrousian

19. Early intervention with recombinant human erythropoietin
   for chemotherapy-induced anemia 509
   G. H. Lyman and J. Glaspy

20. Recombinant human erythropoietin (rhEPO) therapy
   in myelodysplasia 531
   E. Hellström-Lindberg

21. Prediction of response to rhEPO in the anemia of cancer
   541
   Y. Beguin and G. Van Straelen

22. rhEPO in hematopoietic stem cell transplantation 583
   G. Van Straelen and Y. Beguin
## Contents

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>23</td>
<td>Treatment of anemia with rhEPO in radiation oncology</td>
<td>615</td>
</tr>
<tr>
<td>J. Dunst</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Recombinant human erythropoietin in pediatric oncology</td>
<td>635</td>
</tr>
<tr>
<td>C. Hastings and J. Feusner</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>rhEPO in surgical oncology</td>
<td>663</td>
</tr>
<tr>
<td>M. J. Fontaine and L. T. Goodnough</td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>Erythropoiesis, iron metabolism and iron supplementation during erythropoietin therapy</td>
<td>679</td>
</tr>
<tr>
<td>L. T. Goodnough</td>
<td></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>Are there risks for use of iron in cancer patients?</td>
<td>703</td>
</tr>
<tr>
<td>P. Gascón</td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>Metabolic and physiologic effects of rhEPO in anemic cancer patients</td>
<td>713</td>
</tr>
<tr>
<td>K. Lundholm and P. Daneryd</td>
<td></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>Effects of rhEPO on quality of life in anemic cancer patients</td>
<td>729</td>
</tr>
<tr>
<td>S. Chowdhury, J. F. Spicer, and P. G. Harper</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>Thrombosis during therapy with erythropoiesis stimulating agents in cancer</td>
<td>745</td>
</tr>
<tr>
<td>J. Glaspy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>The effect of rhEPO on survival in anemic cancer patients</td>
<td>759</td>
</tr>
<tr>
<td>T. J. Littlewood</td>
<td></td>
<td></td>
</tr>
<tr>
<td>32</td>
<td>From bench to bedside: Neuroprotective effects of erythropoietin</td>
<td>771</td>
</tr>
<tr>
<td>H. Ehrenreich and C. Bartels</td>
<td></td>
<td></td>
</tr>
<tr>
<td>33</td>
<td>rhEPO in patients with anemia and congestive heart failure</td>
<td>793</td>
</tr>
<tr>
<td>D. S. Silverberg, D. Wexler, A. Iaina, S. Steinbruch, Y. Wollman, and D. Schwartz</td>
<td></td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>Cost-effectiveness of treating cancer anaemia</td>
<td>813</td>
</tr>
<tr>
<td>P. Cornes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Addendum</td>
<td></td>
<td>851</td>
</tr>
<tr>
<td>Index</td>
<td></td>
<td>853</td>
</tr>
</tbody>
</table>
Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology
Scientific and Clinical Aspects of Anemia in Cancer
Nowrousian, M.R. (Ed.)
2008, XVIII, 866 p., Hardcover
ISBN: 978-3-211-25223-9